TKTX Transkaryotic Therapies (MM)

TKT To Report Third Quarter Financial Results On November 9, 2004 CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) will report third quarter 2004 financial results on Tuesday, November 9, 2004 before the open of U.S. financial markets. In connection with this announcement, TKT will host a conference call and live audio webcast on November 9, 2004 at 10:00 a.m. Eastern Time. Participants may access the call by dialing (719) 457-2618. This call will also be broadcast live over the Internet at http://www.tktx.com/ under the Investor Information section. A replay of this conference call will be available for two weeks, beginning Tuesday, November 9, 2004 at 1:00 p.m. Eastern Time by dialing (719) 457-0820 and using the access code 953576. In addition, a replay of the webcast will be archived on the TKT website in the Investor Information section. About TKT Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. Outside its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and South America. Additional information about TKT is available on the company's website at http://www.tktx.com/. Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA. CONTACT: Daniella M. Lutz Corporate Communications Manager (617) 349-0205 http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies, Inc. CONTACT: Daniella M. Lutz, Corporate Communications Manager of Transkaryotic Therapies, Inc., +1-617-349-0205 Web site: http://www.tktx.com/ Company News On-Call: http://www.prnewswire.com/comp/120657.html

Copyright